
    
      OBJECTIVES:

      I. To determine the efficacy and safety of alemtuzumab-ofatumumab combination treatment in
      previously untreated CLL.

      OUTLINE:

      Patients receive alemtuzumab subcutaneously (SC) three times a week in weeks 1-18 and
      ofatumumab intravenously (IV) over 4-6 hours on day 1 of weeks 3, 5, 7, 9, 11, 13, 15, and
      17.

      After completion of study treatment, patients are followed up for up to 5 years.
    
  